Meeting
2022 ASCO Annual Meeting
Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC ≥ 4) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled trial.
Authors
Sneh Bhargave Sr.
Aiims, New Delhi, India
Sneh Bhargave Sr., akash kumar , Vinod Sharma , Babita Kataria , Deepam Pushpam , Atul Batra , Raja Pramanik , Sachin Khurana , Ranjit Kumar Sahoo , Prabhat Singh Malik , Sameer Bakhshi , Atul Sharma , Lalit Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
CTRI/2021/03/032165
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS12149)
DOI
10.1200/JCO.2022.40.16_suppl.TPS12149
Abstract #
TPS12149
Poster Bd #
387b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE.
First Author: Yoshimasa Shiraishi
Poster
2021 ASCO Annual Meeting
A randomized, double-blind, multicenter, phase III study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving doxorubicin-cyclophosphamide/epirubicin-cyclophosphamide(AC/EC) based highly emetogenic chemotherapy: CONSOLE-BC.
First Author: Junji Tsurutani